Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10

Biology of Reproduction

Volumn 89, Issue 3, 2013, Pages

  Al Alem, Linah F ^a   McCord, Lauren A ^a   Southard, R Chase ^a   Kilgore, Michael W ^a   Curry, Thomas E ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cancer; Gene expression; Migration; MMPs; Ovary

Indexed keywords

CD147 ANTIGEN; CHORIONIC GONADOTROPIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; ILOMASTAT; LUTEINIZING HORMONE; MATRILYSIN; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; STROMELYSIN 2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CANCER; GENE EXPRESSION; MIGRATION; MMPS; OVARY;

CELL MOVEMENT; CELL PROLIFERATION; CHORIONIC GONADOTROPIN; DIPEPTIDES; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE INHIBITORS; OVARIAN NEOPLASMS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84889594713     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.112.102327     Document Type: Article

References (51)

1. Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer-a short review on biological and clinical/epidemiological aspects. Mol Cell Endocrinol 2007; 269:61-64.
2. Hillard PA. The 5-Minute Obstetrics & Gynecology Consult. Philadelphia: Lippincott Williams & Wilkins; 2008.
3. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771-776.
4. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354: 1586-1590.
5. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995; 346:995-1000.
6. Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, Parazzini F. Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 1994; 9:1673-1675.
7. Kuroda H, Mandai M, Konishi I, Yura Y, Tsuruta Y, Hamid AA, Nanbu K, Matsushita K, Mori T. Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of upregulation of insulin-like growth factor-1 by hCG. Int J Cancer 1998; 76: 571-578.
8. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, Mashiach S, Modan B. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002; 77:324-327.
9. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 2006; 66:3912-3920.
10. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010; 11:9-22.
11. Lahn M, Kohler G, Sundell K, Su C, Li S, Paterson BM, Bumol TF. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 2004; 67:1-10.
12. Carletti MZ, Christenson LK. Rapid effects of LH on gene expression in the mural granulosa cells of mouse periovulatory follicles. Reproduction 2009; 137:843-855.
13. Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y, Terao T. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jundependent signaling pathways. J Biol Chem 2001; 276:2015-2022.
14. Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, Cadungog MG, O'Brien-Jenkins A, Massobrio M, Roby KF, Katsaros D, Gimotty P, et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006; 66:4627-4635.
15. Lee S, Yoon S, Kim DH. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol Oncol 2007; 104:338-344.
16. Naviglio S, Caraglia M, Abbruzzese A, Chiosi E, Di Gesto D, Marra M, Romano M, Sorrentino A, Sorvillo L, Spina A, Illiano G. Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets 2009; 13:83-92.
17. Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res 2006; 12:5336-5345.
18. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253: 269-285.
19. Schropfer A, Kammerer U, Kapp M, Dietl J, Feix S, Anacker J. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer 2010; 10:553.
20. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7:14-23.
21. Lind AK, Dahm-Kahler P, Weijdegard B, Sundfeldt K, Brannstrom M. Gelatinases and their tissue inhibitors during human ovulation: increased expression of tissue inhibitor of matrix metalloproteinase-1. Mol Hum Reprod 2006; 12:725-736.
22. Al-Alem L, Southard RC, Kilgore MW, Curry TE. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARgamma independent manner. PLoS One 2011; 6:e16179.
23. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3:323-327.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2005.
25. Debernardis D, Stanzione S, Ottoboni C, Clerico L, Mancuso T, Parodi S, Russo P. Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines. J Pharmacol Exp Ther 1996; 279:84-90.
26. Gum R, Juarez J, Allgayer H, Mazar A, Wang Y, Boyd D. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene 1998; 17:213-225.
27. Acar A, Onan A, Coskun U, Uner A, Bagriacik U, Atalay F, Unsal DK, Guner H. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med Oncol 2008;25:279-283.
28. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, Yan Y, Clarke J, O'Brien TJ. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): a candidate marker/target for ovarian cancer detection and treatment. Tumor Biol 1999; 20:88-98.
29. Gill JH, Kirwan IG, Seargent JM, Martin SW, Tijani S, Anikin VA, Mearns AJ, Bibby MC, Anthoney A, Loadman PM. MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 2004; 6:777-785.
30. Wang FQ, So J, Reierstad S, Fishman DA. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 2005; 114:19-31.
31. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R. High levels of MMP-2, MMP- 9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999; 17:799-808.
32. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006; 25:99-113.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
34. Stewart SL, Querec TD, Gruver BN, O'Hare B, Babb JS, Patriotis C. Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium. J Cell Physiol 2004; 198:119-124.
35. Cai KQ, Yang WL, Capo-Chichi CD, Vanderveer L, Wu H, Godwin AK, Xu XX. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinog 2007; 46:130-143.
36. Curry TE Jr, Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003; 24:428-465.
37. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006; 231:20-27.
38. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003; 22:145-152.
39. Sharp F. Ovarian Cancer 3. New York: Chapman & Hall; 1994.
40. Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, Lakey R, Middleton J, Cawston TE, Richards CD, Rowan AD. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum 2006; 54:3244-3253.
41. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006; 126:321-334.
42. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008; 118:1367-1379.
43. Sillanpaa S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi- Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S, Kosma VM. Prognostic significance of matrix metalloproteinase-9 (MMP- 9) in epithelial ovarian cancer. Gynecol Oncol 2007; 104:296-303.
44. Kamel H, Abdelazim I, Habib SM, El Shourbagy MA, Ahmed NS. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours. J Obstet Gynaecol Can 2010; 32:580-586.
45. Gershtein ES, Levkina NV, Digayeva MA, Laktionov KP, Tereshkina IV, Kushlinsky NE. Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms. Bull Exp Biol Med 2010; 149:628-631.
46. Cheung LW, Leung PC, Wong AS. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 2006; 66:10902-10910.
47. Voigt H, Vetter-Kauczok CS, Schrama D, Hofmann UB, Becker JC, Houben R. CD147 impacts angiogenesis and metastasis formation. Cancer Invest 2009; 27:329-333.
48. Agrawal SM, Yong VW. The many faces of EMMPRIN - roles in neuroinflammation. Biochim Biophys Acta 2011; 1812:213-219.
49. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 2000; 9:2167-2177.
50. Solar P, Sytkowski AJ. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. Cancer Lett 2011; 309:11-18.
51. Mertens-Walker I, Bolitho C, Baxter RC, Marsh DJ. Gonadotropininduced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase Cfdeltag. Endocr Relat Cancer 2010; 17:335-349.